bovhyaluronidase azoxymer

PreclinicalSmall molecule

bovhyaluronidase azoxymer is one of 102 small molecule programs targeting Interstitial Lung Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

101

Competitors

Pipeline

Status by Indication[3][1]

Indication

Interstitial Lung DiseaseActive, not recruiting

EndometriosisActive, not recruiting

Benign Prostatic HyperplasiaActive, not recruiting

Interstitial Lung DiseasePreclinical

Active, not recruiting

EndometriosisPreclinical

Active, not recruiting

Benign Prostatic HyperplasiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

60 competitors in Endometriosis

#DrugCompanyPhaseTrials

Danocrine

Sanofi

Approved

5 2

Bayer Aspirin

Bayer

Approved

2 3

Orilissa

AbbVie

Phase 3

16 4

Estrace

IC-Green

4 6

Ketalar

AAultman Health Foundation

Approved

2 7

Jadelle

IItalian Network for Tumor Biotherapy Foundation

Approved

1 8

Implanon

OOrganon and Co

Approved

1 9

Zocor

OOrganon and Co

Approved

1 10

Flagyl

DDePuy Orthopaedics

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Interstitial Lung Disease1 trial

Study of Longidaze in the Prevention & Treatment of Pulmonary Fibrosis, Interstitial Lung Diseases Caused by COVID-19

Completed·NNPO Petrovax··NCT04645368·160 enrolled

Endometriosis1 trial

Study of the Efficacy and Safety of Longidaze® for the Treatment of Patients With External Genital Endometriosis

Unknown status·NNPO Petrovax··NCT04962620·149 enrolled

Benign Prostatic Hyperplasia1 trial

Efficacy and Safety of Longidaze in the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia

Completed·NNPO Petrovax·N/A·NCT06568718·229 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for bovhyaluronidase azoxymer. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — bovhyaluronidase azoxymer compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for bovhyaluronidase azoxymer. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NPO Petrovax company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNPO Petrovax

bovhyaluronidase azoxymer

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Interstitial Lung Disease1 trial

Endometriosis1 trial

Benign Prostatic Hyperplasia1 trial

References

Drug Info

Quick Facts

Related News